Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI)

NCT05381038 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05381038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05381038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI)
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 13, 2023
Completion date
April 4, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastrointestinal cancer, solid tumor